Last updated: September 2, 2026
Regorafenib, marketed by Bayer as Stivarga, is a mature multikinase inhibitor with global sales of approximately €400 million annually. Its core commercial value comes from colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. Revenue growth has largely stalled as treatment sequencing has become more competitive, while oral oncology access restrictions and treatment toxicity limit broader uptake.
The product remains commercially relevant because it is differentiated by activity across three tumor types, established clinical evidence, and global regulatory approvals. Its main risks are generic entry, competing targeted therapies, immuno-oncology combinations, and declining use after earlier-line treatment options fail.
What is regorafenib and which cancers does it treat?
Regorafenib is an oral multikinase inhibitor that inhibits signaling through VEGFR1-3, TIE2, KIT, RET, RAF kinases, PDGFR, and FGFR pathways. Bayer sells it under the Stivarga brand.
The U.S. Food and Drug Administration approved Stivarga for:
- Previously treated metastatic colorectal cancer.
- Previously treated unresectable or metastatic gastrointestinal stromal tumor after imatinib and sunitinib.
- Previously treated hepatocellular carcinoma after sorafenib.
FDA approval timeline
| Milestone |
Date |
Commercial relevance |
| First FDA approval for metastatic colorectal cancer |
September 2012 |
Established initial market |
| FDA approval for GIST |
February 2013 |
Added an orphan-oncology indication |
| FDA approval for hepatocellular carcinoma |
April 2017 |
Expanded use into liver cancer |
| Current U.S. dosage form |
40 mg tablets |
Standard daily dose is 160 mg for 21 days of a 28-day cycle |
The approved colorectal cancer and GIST regimens generally use 160 mg once daily for three weeks followed by one week off. In practice, dose reductions are common because of hand-foot skin reaction, fatigue, hypertension, diarrhea, hepatotoxicity, and other adverse events. Dose optimization has become part of the commercial strategy in some markets because tolerability affects persistence and treatment duration.
How large is the regorafenib market?
Regorafenib is a global specialty-oncology product with annual Bayer sales near €400 million. Bayer reports Stivarga sales within its Pharmaceuticals segment rather than as a separate public company, and the company does not disclose product-level profit, patient counts, or country-level contribution in a consistent format.
Bayer Stivarga financial trajectory
| Period |
Approximate Bayer sales |
Direction |
| 2018-2019 |
€350 million to €400 million |
Growth from broader adoption |
| 2020-2021 |
About €400 million to €450 million |
Relative stability |
| 2022-2023 |
About €400 million to €450 million |
Mature-product plateau |
| 2024 |
Approximately €400 million |
Stable to modestly lower |
The product’s financial trajectory reflects a mature branded oncology medicine rather than a high-growth launch asset. Revenue has benefited from continued use in later-line colorectal cancer and GIST, but new-patient growth has been constrained by:
- Earlier use of targeted therapies and immunotherapies.
- Competition from trifluridine/tipiracil, fruquintinib, and other later-line colorectal cancer products.
- Ripretinib’s position in advanced GIST.
- Treatment discontinuation caused by tolerability issues.
- Pricing pressure and tender-based procurement outside the United States.
Bayer’s reported sales indicate that regorafenib remains a material product, but it is no longer a major driver of the company’s pharmaceutical growth. Its value is primarily cash generation, geographic reach, and portfolio durability.
What markets drive regorafenib revenue?
Colorectal cancer
Colorectal cancer is the broadest commercial indication. Regorafenib is used after progression on fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF therapy, and anti-EGFR therapy when clinically appropriate.
Its position is challenged by:
- Trifluridine/tipiracil, marketed as Lonsurf.
- Trifluridine/tipiracil plus bevacizumab.
- Fruquintinib, marketed in the United States as Fruzaqla.
- Clinical trials of molecularly selected therapies.
- Rechallenge strategies involving EGFR inhibitors in selected patients.
Regorafenib retains value where physicians seek an established oral multikinase inhibitor, but its use is highly dependent on treatment sequencing and patient performance status.
Gastrointestinal stromal tumor
GIST is a smaller but strategically important indication. Regorafenib is approved after imatinib and sunitinib, placing it in a heavily pretreated population.
Ripretinib, marketed as Qinlock by Deciphera Pharmaceuticals, is the principal branded competitor in later-line GIST. Ripretinib is approved after treatment with three or more kinase inhibitors, including imatinib. The products overlap in the fourth-line and later-line setting, although treatment selection depends on mutation profile, prior therapy, tolerability, and physician preference.
Hepatocellular carcinoma
Regorafenib is approved for patients previously treated with sorafenib. Its commercial position weakened as first-line systemic therapy shifted toward immunotherapy-based regimens and combination therapy.
Current HCC competition includes:
- Atezolizumab plus bevacizumab.
- Durvalumab plus tremelimumab.
- Nivolumab-based strategies in selected settings.
- Sorafenib and lenvatinib in appropriate patients.
- Cabozantinib.
- Ramucirumab for biomarker-selected patients.
The HCC indication provides diversification but is less likely to produce substantial growth because many patients now receive immunotherapy combinations before regorafenib.
When does regorafenib lose market exclusivity?
Regorafenib’s commercial exclusivity is governed by a combination of patents, FDA regulatory exclusivity, national patent rights, and generic approval timing. FDA regulatory exclusivity has expired for the original U.S. approvals. The key commercial question is patent exposure, not FDA orphan or new-chemical-entity exclusivity.
U.S. exclusivity framework
| Protection |
Status |
| Five-year new chemical entity exclusivity |
Expired |
| Seven-year orphan exclusivity for GIST |
Expired |
| Pediatric exclusivity |
Must be assessed against the specific FDA designation and patent listing |
| Orange Book patents |
Control the timing of ANDA approval and potential generic entry |
| Formulation and method patents |
May delay or narrow generic competition if enforceable |
The precise U.S. generic-entry date depends on the active Orange Book listings, patent certifications, litigation, settlement terms, and any 180-day first-filer exclusivity. A patent expiry date alone does not establish the actual launch date.
What patents protect Stivarga and regorafenib?
Regorafenib protection has historically included composition-of-matter, pharmaceutical composition, dosage, formulation, and method-of-use rights. Bayer and affiliated entities have prosecuted patent families covering the active compound and its use in cancer.
Main patent categories
Active compound patents
These patents protect regorafenib or closely defined chemical compounds. Composition patents provide the strongest protection because an ANDA applicant generally cannot avoid infringement by using a different tablet formulation.
Pharmaceutical composition patents
These rights can cover regorafenib in combination with excipients, particular salt or polymorph forms, particle characteristics, or defined dosage forms. Their practical value depends on whether the generic product must practice the claimed limitations.
Method-of-use patents
Method claims may cover treatment of colorectal cancer, GIST, HCC, or treatment after specified prior therapies. Their value is limited by the ability of generic applicants and physicians to avoid or challenge the claimed use.
Manufacturing patents
Manufacturing rights can cover intermediates, synthetic routes, crystallization, impurity control, and process conditions. These patents may create supply-chain friction but usually do not prevent a generic company from entering if it can use a non-infringing process.
The current Orange Book should be used for the authoritative list of U.S. patents and pediatric exclusivity associated with Stivarga. FDA regulations permit applicants to certify against listed patents through Paragraph I, II, III, or IV certifications, depending on the patent’s status and the applicant’s position on timing.
What is the Orange Book status of regorafenib?
Stivarga is an FDA-approved small-molecule drug listed in the Orange Book. The Orange Book identifies the reference listed drug, approved strengths, dosage form, therapeutic-equivalence information, and applicable patent or exclusivity data.
The commercial implications are:
- An ANDA applicant must address listed patents.
- A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed.
- Bayer may file patent litigation within 45 days of receiving a valid Paragraph IV notice.
- A timely suit can trigger a 30-month stay of ANDA approval, subject to statutory exceptions and court decisions.
- Generic substitution depends on FDA therapeutic-equivalence coding and state substitution law.
Orange Book listing does not guarantee that a patent will survive litigation. It identifies the regulatory barriers an ANDA applicant must address.
Which companies are challenging regorafenib?
The principal competitive threat comes from generic manufacturers rather than biosimilar developers. Regorafenib is a chemically synthesized small molecule, so the relevant pathway is an ANDA, not a biosimilar application.
Potential generic competitors include companies with oncology-tablet manufacturing capabilities in the United States, India, China, and Europe. Commercial entry requires:
- Bioequivalence to the reference product.
- Compliance with FDA quality requirements.
- Ability to manufacture a potent oncology compound.
- Reliable supply of active pharmaceutical ingredient.
- Resolution of Orange Book patents.
- Sufficient reimbursement and distribution economics.
No biosimilar risk exists for regorafenib. The product’s risk is generic substitution.
What patent litigation and settlements affect regorafenib?
Regorafenib litigation risk should be evaluated through three channels:
- Paragraph IV notices and ANDA litigation in the U.S. District Courts.
- European and national patent challenges.
- Patent opposition and revocation proceedings involving Bayer patent families.
A settlement can permit an authorized generic, a license date, a geographic launch, or an earlier entry date than the latest patent expiry. Settlement terms may also restrict product labeling, manufacturing sources, or launch conditions.
The financial impact depends on whether an entrant launches:
- Before patent expiry through settlement.
- At patent expiry.
- After a successful invalidity or non-infringement decision.
- With a limited label that omits patented indications.
- As an authorized generic supplied by Bayer or its licensee.
For regorafenib, a label carve-out could be commercially meaningful because the drug has multiple indications. A generic company that omits a patented method may still compete in non-protected indications, depending on the scope of the remaining claims and applicable regulatory rules.
How strong is the regorafenib patent estate?
Regorafenib’s strongest protection historically came from its active-compound patent family. That protection is weaker once the core patent term expires or becomes vulnerable to validity challenges.
The remaining estate is likely less robust when it relies on:
- Narrow formulation limitations.
- Specific dose schedules.
- Patient-selection claims.
- Use after defined prior therapies.
- Process claims that do not control the final marketed tablet.
Patent strength should be assessed claim by claim. A large number of patent documents does not equal broad market protection. The key questions are whether the patent covers the active ingredient, whether the claims survive validity review, whether the relevant claims are listed in the Orange Book, and whether a generic can design around them.
How does regorafenib compare with competing drugs?
| Product |
Company |
Main overlapping market |
Competitive position |
| Stivarga |
Bayer |
mCRC, GIST, HCC |
Established later-line multikinase inhibitor |
| Lonsurf |
Taiho/Servier |
mCRC |
Strong later-line colorectal competitor |
| Fruzaqla |
Takeda |
mCRC |
Newer targeted colorectal option |
| Qinlock |
Deciphera |
GIST |
Important later-line GIST competitor |
| Cabometyx |
Exelixis |
HCC and other cancers |
Competes in liver cancer and broader oncology |
| Nexavar |
Bayer |
HCC |
Earlier-generation Bayer TKI |
| Generic sorafenib |
Multiple companies |
HCC |
Low-cost alternative in selected settings |
Regorafenib’s advantage is its multi-indication footprint and established clinical use. Its disadvantages are toxicity, later-line positioning, and the increasing availability of biomarker-directed or immunotherapy-based alternatives.
What generic launch scenarios exist for regorafenib?
Scenario 1: No generic entry before core patent expiry
This outcome preserves Bayer pricing and revenue until the principal blocking patent expires. Revenue would still decline gradually because of competitive substitution and payer pressure.
Scenario 2: One generic entrant
A single entrant may launch with limited discounting, particularly if first-filer rights or settlement terms restrict competition. Bayer’s erosion would be meaningful but slower than in a multi-entrant market.
Scenario 3: Multiple generic entrants
Several ANDA approvals could produce rapid price erosion. Small-molecule oncology products often experience substantial price compression once multiple suppliers are available, although the rate depends on channel concentration and manufacturing complexity.
Scenario 4: Authorized generic
An authorized generic would allow Bayer to participate in post-exclusivity volume while protecting some market share. It could reduce the commercial advantage of independent ANDA entrants.
What revenue exposure does Bayer face?
Regorafenib is important enough to contribute recurring revenue but is not among Bayer’s largest pharmaceutical products. A 50% decline from a €400 million annual base would reduce Bayer Pharmaceuticals revenue by about €200 million. The absolute exposure is manageable at group scale, but the product has higher strategic value in markets where it remains one of few available later-line oncology treatments.
Revenue erosion will depend on:
- Timing of U.S. generic entry.
- Generic penetration in Europe and Japan.
- Bayer’s ability to maintain branded use in HCC and GIST.
- Price controls and tender outcomes.
- Competitor clinical data.
- Dose-optimization strategies that improve persistence.
Key Takeaways
- Regorafenib is a mature Bayer oncology product with annual sales near €400 million.
- Its three approved indications are metastatic colorectal cancer, GIST, and previously treated HCC.
- Colorectal cancer provides the broadest market, while GIST supports specialty demand and HCC adds diversification.
- FDA regulatory exclusivity has expired; patent status determines generic timing.
- Regorafenib faces generic risk, not biosimilar risk.
- Lonsurf, Fruzaqla, Qinlock, cabozantinib, immunotherapy combinations, and generic sorafenib shape the competitive environment.
- The strongest patent protection historically came from composition-of-matter rights; later formulation and method patents are generally narrower.
- Bayer’s likely financial trajectory is stable-to-declining revenue rather than renewed high growth.
- A single generic entrant would create gradual erosion; multiple entrants could produce rapid price and share loss.
- Current Orange Book listings, Paragraph IV activity, and any settlement agreement are the decisive indicators for U.S. launch timing.
FAQs
Is regorafenib still commercially important to Bayer?
Yes. Stivarga is a mature but durable oncology product that generates approximately €400 million in annual sales and remains part of Bayer’s recurring pharmaceutical revenue base.
Is there a generic version of Stivarga?
Generic regorafenib requires FDA approval through the ANDA pathway and resolution of applicable Orange Book patents. Availability differs by jurisdiction and should not be inferred from patent expiry alone.
Does regorafenib have biosimilar competition?
No. Regorafenib is a small-molecule chemical drug. Competition would come from generic tablets, not biosimilars.
Which drug is the closest competitor to regorafenib in GIST?
Ripretinib, marketed as Qinlock, is the principal branded competitor in later-line GIST. Imatinib, sunitinib, and other kinase inhibitors remain relevant earlier in the treatment sequence.
Which drug most directly challenges regorafenib in colorectal cancer?
Trifluridine/tipiracil, particularly in combination with bevacizumab, and fruquintinib are among the most direct later-line competitors. Their impact varies by country, reimbursement, molecular profile, and treatment guidelines.
References
-
Bayer AG. (2024). Annual report 2024. Bayer AG.
-
Bayer AG. (2023). Annual report 2023. Bayer AG.
-
U.S. Food and Drug Administration. (2012). FDA approves new treatment for advanced colorectal cancer. FDA.
-
U.S. Food and Drug Administration. (2013). FDA approves Stivarga for gastrointestinal stromal tumors. FDA.
-
U.S. Food and Drug Administration. (2017). FDA approves Stivarga for hepatocellular carcinoma. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Grothey, A., Sobrero, A. F., Shields, A. F., Yoshino, T., Waser, G., Lenz, H.-J., ... Van Cutsem, E. (2013). Regorafenib monotherapy for previously treated metastatic colorectal cancer: A multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet, 381(9863), 303-312.
-
Demetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., ... Casali, P. G. (2013). Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. The Lancet, 381(9863), 295-302.
-
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., ... Llovet, J. M. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment. The Lancet, 389(10064), 56-66.
-
U.S. Food and Drug Administration. (2024). Stivarga prescribing information. Bayer HealthCare Pharmaceuticals Inc.
